United Therapeutics Corporation (NASDAQ: UTHR) announced today the signing of an agreement with DEKA Research & Development Corp. for the development of a potential technology breakthrough in the subcutaneous delivery of Remodulin® (treprostinil) Injection to patients with pulmonary arterial hypertension (PAH) via a pre-filled semi-disposable pump system.
U.S. News & World Report is pleased to announce the 2014 STEM Leadership Hall of Fame, honored during the U.S. News STEM Solutions conference. In choosing the honorees, U.S. News sought out leaders who, among other things, have achieved measurable results in the science, technology, engineering, and math fields; challenged established processes and conventional wisdom; inspired a shared vision; and motivated legions of aspiring STEM professionals.
Outgoing D.C. Mayor Vincent Gray gave the city’s tech scene some love as one of his final acts, signing a somewhat controversial tax cut into law. The capital gains tax on returns from investments in certain tech companies was lowered to 3 percent.
Here are a few thoughts on the cut from techs I spoke with…
Governmental agencies face a wide spectrum of challenges in creating mHealth apps, ranging from a changing development culture to potential litigious issues, revealed a new report published in the Journal of Medical Internet Research.
Anne Arundel County’s economic development chief took to LinkedIn in search of a new executive director of the Chesapeake Innovation Center — and he’s dangling a big carrot.
Robert L. Hannon, president and CEO of Anne Arundel Economic Development Corp., is spreading the word that he’s looking for an executive director for the agency’s technology incubator who has a background in small-business/technology development, technology commercialization, entrepreneurship and five years professional work experience. The position’s salary will range from $110,000 to $130,000, with an estimated benefits
Last spring Laura Murphy, then 28 years old, went to a doctor to find out if a harmless flap of skin she had always had on the back of her neck was caused by a genetic mutation. Once upon a time, maybe five years ago, physicians would have focused on just that one question. But today doctors tend to run tests that pick up mutations underlying a range of hereditary conditions. Murphy learned not only that a genetic defect was indeed responsible for the flap but also that she had another inherited genetic mutation.
The CMS Innovation Center paid $2.6 billion through September to hospitals, doctors and others through nearly two dozen programs that tested new ways to deliver healthcare and pay for it.
SHUTTLE Pharmaceuticals, a privately held company, today announced it has been awarded a fast-track Phase I/II contract #HHSN261201400013C by the National Institutes of Health (NIH) under its Small Business Innovation Research (SBIR) program. The $ 1.62 million contract will fund the initial development of IPdR (5-iodo-2-pyrimidinone-2-deoxyribose), a prodrug of the radiation sensitizer IUdR (5-iodo-2-deoxyuridine). The contract is to determine the scientific merit, feasibility and potential for commercialization of oral IPdR for use as a radiation sensitizer for the treatment of rectal cancers. The NIH contract provides funds to cover a portion of the costs for initiating a Phase I trial in GI cancers and development of companion diagnostics for analyzing clinical specimens from Phase I patients.
Ah, the elevator pitch. A favorite tool of the networking masses. A rite of passage of sorts. You’ve heard the scenario: you step into an elevator and go up one floor. The elevator doors open and in walks the client of your dreams. They start some small talk and ask, “What do you do?” and you’ve got the rest of the elevator ride to respond. How do you answer that in 20 seconds in such a way that gets them interested? The answer is simple. You need an elevator pitch for your elevator pitch.
Roche Holding AG said US health regulators have approved its Ebola test for emergency use in response to the world’s worst outbreak of the disease in West Africa.
The US Food and Drug Administration (FDA) has approved Roche’s LightMix Ebola Zaire rRT-PCR Test for use on patients with signs and symptoms of Ebola Zaire virus infection, the Swiss drugmaker said in a statement.
